GlobeNewswire Inc.··Agomab Therapeutics NvAgomab Raises $208M in IPO, Extends Runway to 2029 Amid Pipeline Progress
Agomab Therapeutics raised $208M in February 2026 IPO and reported €116.5M cash, funding operations into H1 2029 while advancing two lead drug candidates.
AGMBIPOclinical-stage biopharmaceutical